Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including ...

The earliest iteration of LNPs was the development of liposomes in the 1960s, with the first liposome-based drug product, Doxil, receiving FDA approval in 1995. In the early 1990s, a second generation ...

Engineered nanoparticles can improve cancer immunotherapy by delivering drugs, antigens, and genetic payloads with greater ...

Encapsulating an active substance in a liposome or lipid nanoparticle can minimize cytotoxicity and increase blood circulation by bypassing the immune system. Several techniques can improve a drug's ...

To create A1 lipid nanoparticles for delivering mRNA to target cells, scientists at the University of Pennsylvania used A3 coupling. A3 refers to the amine–aldehyde–alkyne coupling reaction, which the ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...

Lipid-based nanoparticles (LNPs) are becoming an essential platform in pharmaceutical research and manufacturing. They’re used to improve the delivery of mRNA, enhance the absorption of poorly ...

Lipid nanoparticles (LNPs) have become the gold standard in non-viral gene delivery technologies, exemplified by the approval of the LNP messenger RNA (mRNA) vaccines against SARS-CoV-2. Since then, ...

Scientists have discovered that the internal shape of tiny drug-delivery particles—called lipid nanoparticles—has a big impact on how well our cells absorb them, paving the way to more efficient ...

From vaccines to personalized cancer therapies, scientists are studying the use of mRNA across many clinical applications. However, there are several factors that are unique to mRNA drug product ...